Multiple choices for HIV therapy with integrase strand transfer inhibitors
<p>Abstract</p> <p>Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3...
Main Authors: | Raffi Francois, Wainberg Mark A |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-12-01
|
Series: | Retrovirology |
Subjects: | |
Online Access: | http://www.retrovirology.com/content/9/1/110 |
Similar Items
-
Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
by: Thibault Mesplède, et al.
Published: (2015-07-01) -
Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals
by: Pablo López, et al.
Published: (2021-03-01) -
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01) -
Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors
by: Michał S. Barski, et al.
Published: (2019-08-01) -
HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
by: Vogel Martin, et al.
Published: (2009-11-01)